secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-08-14T12:30:12+00:00
Accession:  0001193125-26-350596
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio partner Mabworks doses first IgA nephropathy patient in Phase 2 China trial
--------------------------------------------------------------------------------

- Beijing Mabworks Biotech announced first patient dosed in Phase 2 trial for immunoglobulin A nephropathy in China.
- Trial is conducted in collaboration with Climb Bio, Inc.; announcement made August 13, 2026.
- Climb Bio disclosed the milestone via Form 8-K on August 14, 2026; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/0001193125-26-350596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/d328636d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-350596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer